Nuformix PLC (LSE:NFX)'s (Nuformix PLC (LSE:NFX)) executive director Dr Dan Gooding explains to Proactive the latest developments with its treatment to combat Idiopathic Pulmonary Fibrosis (IPF).
The NXP002 programme, using a repurposed version of the existing drug 'tranilast', can be delivered by a range of nebulisers with very high doses appearing to be well-tolerated.
Nuformix will next look to initiate studies in 3D human IPF lung tissue, he says.
#Nuformix #Idiopathic Pulmonary Fibrosis #fibrosis